These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29850358)

  • 61. Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes.
    Church LD; McDermott MF
    Expert Rev Clin Immunol; 2010 Nov; 6(6):831-41. PubMed ID: 20979548
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Schnitzler's syndrome].
    Oborilová A; Adam Z
    Vnitr Lek; 1998 Jul; 44(7):423-7. PubMed ID: 9748880
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Canakinumab for the treatment of TNF-receptor associated periodic syndrome.
    La Torre F; Caparello MC; Cimaz R
    Expert Rev Clin Immunol; 2017 Jun; 13(6):513-523. PubMed ID: 28454496
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Partial response to cyclosporine in a patient with Schnitzler's syndrome.
    Carbone J; Paravisini A; Sarmiento E; Rodríguez-Molina J; Fernández-Cruz E
    Allergol Immunopathol (Madr); 2007; 35(2):71-3. PubMed ID: 17428403
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Schnitzler's syndrome: report of a new case and a review of the literature.
    Puddu P; Cianchini G; Girardelli CR; Colonna L; Gatti S; de Pita O
    Clin Exp Rheumatol; 1997; 15(1):91-5. PubMed ID: 9093781
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Free circulating interleukin-18 is increased in Schnitzler syndrome: a new autoinflammatory disease?
    Migliorini P; Del Corso I; Tommasi C; Boraschi D
    Eur Cytokine Netw; 2009 Sep; 20(3):108-11. PubMed ID: 19825519
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Urticarial vasculitis and urticarial autoinflammatory syndromes.
    Marzano AV; Tavecchio S; Venturini M; Sala R; Calzavara-Pinton P; Gattorno M
    G Ital Dermatol Venereol; 2015 Feb; 150(1):41-50. PubMed ID: 25586657
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS).
    La Torre F; Muratore M; Vitale A; Moramarco F; Quarta L; Cantarini L
    Rheumatol Int; 2015 Nov; 35(11):1943-7. PubMed ID: 26048626
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Schnitzler's syndrome: a broader clinical spectrum.
    Berdy SS; Bloch KJ
    J Allergy Clin Immunol; 1991 Apr; 87(4):849-54. PubMed ID: 1826507
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Schnitzler's syndrome presenting as fever of unknown origin (FUO). The role of cytokines in its systemic features.
    de Kleijn EM; Telgt D; Laan R
    Neth J Med; 1997 Oct; 51(4):140-2. PubMed ID: 9446924
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial.
    Rissanen A; Howard CP; Botha J; Thuren T;
    Diabetes Obes Metab; 2012 Dec; 14(12):1088-96. PubMed ID: 22726220
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Canakinumab: in patients with cryopyrin-associated periodic syndromes.
    Curran MP
    BioDrugs; 2012 Feb; 26(1):53-9. PubMed ID: 22168385
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Development and implementation of the AIDA international registry for patients with Schnitzler's syndrome.
    Sota J; Vitale A; Więsik-Szewczyk E; Frassi M; Lopalco G; Emmi G; Govoni M; de Paulis A; Marino A; Gidaro A; Monti S; Opris-Belinski D; Pereira RMR; Jahnz-Rózyk K; Gaggiano C; Crisafulli F; Iannone F; Mattioli I; Ruffilli F; Mormile I; Rybak K; Caggiano V; Airò P; Tufan A; Gentileschi S; Ragab G; Almaghlouth IA; Aboul-Fotouh Khalil A; Cattalini M; La Torre F; Tarsia M; Giardini HAM; Ali Saad M; Bocchia M; Caroni F; Giani T; Cinotti E; Ruscitti P; Rubegni P; Dagostin MA; Frediani B; Guler AA; Della Casa F; Maggio MC; Recke A; von Bubnoff D; Krause K; Balistreri A; Fabiani C; Rigante D; Cantarini L
    Front Med (Lausanne); 2022; 9():931189. PubMed ID: 35924038
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A case of urticarial vasculitis associated with macroglobulinemia (Schnitzler's syndrome).
    Morita A; Sakakibara S; Yokota M; Tsuji T
    J Dermatol; 1995 Jan; 22(1):32-5. PubMed ID: 7897021
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Long-term effectiveness and safety of canakinumab in pediatric familial Mediterranean fever patients.
    Gülez N; Makay B; Sözeri B
    Mod Rheumatol; 2020 Jan; 30(1):166-171. PubMed ID: 30556769
    [No Abstract]   [Full Text] [Related]  

  • 76. Schnitzler's syndrome: report of a case with progression to Waldenström's macroglobulinaemia.
    Welsh B; Tate B
    Australas J Dermatol; 1999 Nov; 40(4):201-3. PubMed ID: 10570556
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Successful use of anakinra to treat refractory Schnitzler's syndrome.
    Dybowski F; Sepp N; Bergerhausen HJ; Braun J
    Clin Exp Rheumatol; 2008; 26(2):354-7. PubMed ID: 18565263
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey.
    Rossi-Semerano L; Fautrel B; Wendling D; Hachulla E; Galeotti C; Semerano L; Touitou I; Koné-Paut I;
    Orphanet J Rare Dis; 2015 Feb; 10():19. PubMed ID: 25758134
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical characterization and long-term follow-up of Schnitzler syndrome.
    Gameiro A; Gouveia M; Pereira M; Tellechea O; Gonçalo M
    Clin Exp Dermatol; 2016 Jul; 41(5):461-7. PubMed ID: 27238847
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Muckle-Wells syndrome: clinical perspectives.
    Tran TA
    Open Access Rheumatol; 2017; 9():123-129. PubMed ID: 28744167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.